Protagonist Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Continued focus on Phase 3 VERIFY study of rusfertide in polycythemia vera (PV) Presented new, positive data from Phase 2 REVIVE study of rusfertide in PV at the 2022 ASCO Annual Meeting and the EHA2022 Congress Strong cash position, with cash runway through end of 2024 NEWARK, Calif.,...

Click to view original post